Stifel Nicolaus Forecasts Strong Price Appreciation for Celcuity (NASDAQ:CELC) Stock

Celcuity (NASDAQ:CELC) had its price target lifted by research analysts at Stifel Nicolaus from $115.00 to $125.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 10.28% from the company’s current price.

Several other research analysts have also recently issued reports on the stock. Wolfe Research reiterated an “outperform” rating and set a $110.00 target price on shares of Celcuity in a report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 price target on shares of Celcuity in a research report on Thursday. Wells Fargo & Company started coverage on shares of Celcuity in a research note on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective on the stock. Finally, Jefferies Financial Group lifted their price objective on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Stock Up 2.8%

Shares of Celcuity stock traded up $3.13 during trading on Thursday, hitting $113.35. 189,359 shares of the stock traded hands, compared to its average volume of 708,319. The firm has a market cap of $5.24 billion, a P/E ratio of -30.65 and a beta of 0.38. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32. The stock’s fifty day simple moving average is $109.32 and its 200 day simple moving average is $90.27.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.77% of the stock is owned by company insiders.

Institutional Trading of Celcuity

A number of institutional investors have recently modified their holdings of the company. Ogorek Anthony Joseph NY ADV acquired a new stake in Celcuity in the 3rd quarter worth approximately $27,000. EverSource Wealth Advisors LLC raised its holdings in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE raised its holdings in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the period. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Celcuity during the fourth quarter worth $42,000. 63.33% of the stock is currently owned by institutional investors.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Needham reaffirmed a “buy” and raised its price target to $122, signaling incremental analyst optimism and indicating upside versus the current market level. Needham Price Target Raise
• Positive Sentiment: Q4 results beat estimates on the bottom line: EPS of ($0.73) beat consensus ($1.06) — a clear near-term financial beat that reduces near-term downside risk vs. expectations. Earnings Release / Transcript
• Positive Sentiment: Company guidance/updates and analyst commentary outline a potential ~ $2.5B annual peak revenue opportunity for gedatolisib if pivotal milestones and commercial launch succeed — a large-market thesis that supports long-term upside. Gedatolisib Peak Revenue Article
• Positive Sentiment: Coverage noting the breast cancer program is nearing regulatory milestones/approval has increased investor excitement about an upcoming value-inflection event. Drug Approval Coverage
• Neutral Sentiment: Earnings call/transcript highlights underscore that the company is still operating at a loss while advancing the program — typical for a clinical‑stage biotech and a reminder of execution risk even as the pipeline shows promise. Earnings Call Transcript
• Neutral Sentiment: Short-interest data reported in several sources appears anomalous (shows zero shares), so recent headlines about “large increases” are likely unreliable; no clear short-squeeze signal from the reported figures.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.